COMP <GO>
IDXX vs LLY // PIOTROSKI F-SCORE QUALITY
IDEXX Laboratories Inc. (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: IDXX 5
— LLY 9
■ METRIC PARITY
LAST: $551.21 (-4.30%) • MKT CAP: $45.38B
piotroski-score
9/9
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.33T
piotroski-score
9/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IDXX VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | IDXX | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 61.80% | 83.64% | -21.84 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 29.60% | 32.36% | -2.76 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 31.1x | 36.4x | -5.32 | IDXX | /valuation <GO> |
| Free Cash Flow Yield | 2.33% | 2.30% | +0.03 | IDXX | /fcf-yield <GO> |
| Operating Margin | 31.60% | 40.21% | -8.61 | LLY | /operating-margins <GO> |
| Net Profit Margin | 24.60% | 31.90% | -7.30 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 10.40% | 45.51% | -35.11 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 20.99 | 9.29 | +11.70 | IDXX | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 9/9 | 9/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.50% | 6.77% | -0.27 | IDXX | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 52.4 | 77.9 | -25.49 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.89 | 0.51 | +0.38 | IDXX | /macro-sensitivity <GO> |
| Forward P/E Multiple | 39.8x | 26.3x | +13.55 | LLY | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $45.38B | $1.33T | -$1.29T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | IDXX REV | LLY REV | IDXX GROSS % | LLY GROSS % | IDXX FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $4.30B | $65.18B | 61.8% | 83.0% | $1.06B | $16.81B |
| FY 2024 | $3.90B | $45.04B | 61.0% | 81.3% | $808.1M | $8.82B |
| FY 2023 | $3.66B | $34.12B | 44.0% | 79.3% | $741.8M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IDXX // BETA 0.89
LLY // BETA 0.51